Andrew Allen

Andrew Allen currently serves as a member of the Board of Directors for Adaptimmune and Verge Genomics, and as Executive Chairman for Peptone and Revitope Oncology. Previously, Andrew held positions as President, CEO & Co-Founder of Gritstone bio, and as a Board Member for TCR² Therapeutics Inc. until its acquisition by Adaptimmune in June 2023. Andrew's experience also includes board roles at Sierra Oncology, Epizyme, and Cell Design Labs, with significant responsibilities in the biotechnology sector, including leadership roles at Clovis Oncology. Andrew holds an MA BM BCh from the University of Oxford and a Doctor of Philosophy (PhD) from Imperial College London.